Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Micron Technology, Inc. (MU) vs Sana Biotechnology Inc (SANA) Price & Performance

Micron Technology, Inc.Trade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Micron Technology, Inc. vs Sana Biotechnology Inc — how do they compare? Micron Technology, Inc. trades at $978.38 (market cap $977.44B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Micron Technology, Inc. is far larger — about 1118.6× Sana Biotechnology Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

MUSANA
Market Cap
$977.44B$873.84M
Sector
TechnologyHealth
52-Week High
$1.21K$5.92
52-Week Low
$104.88$2.68
Enterprise Value
$957.80B$848.03M
Dividend Yield
0.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Micron Technology, Inc.

Micron Technology (MU) surged 14.36% to $970.82, driven by strong AI memory demand and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 19.56 and net income margin of 55.91%, supported by three consecutive quarterly earnings beats. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels suggesting potential rebound. Recent news highlights AI-driven memory chip demand and strategic customer agreements fueling growth optimism.

Outlook remains bullish due to AI super-cycle tailwinds and projected 2026 revenue of $90.3B, though risks include cyclical semiconductor demand and high valuation multiples. Analyst consensus strongly favors Buy with a $1,550 price target, indicating ~60% upside potential from current levels.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.

While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Micron Technology, Inc.

Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.

Read more on MU

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA